Q-omics provides the consensus-scored UBTD1 profile across patient tissues and cancer cell-line models. UBTD1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UBTD1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, UBTD1 RNA expression shows 17,993 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where UBTD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBTD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBTD1 survival associations across molecular data types. UBTD1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBTD1 RNA expression–survival associations across cancer types. High UBTD1 expression shows unfavorable associations in ACC, BLCA, UVM, OV and READ, but favorable associations in LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for UBTD1 RNA expression.
This table summarizes UBTD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for UBTD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBTD1 shows lower tumor expression in KIRC, LUAD, KICH and LUSC and higher tumor expression in COAD and THCA. The COAD box plot shows higher UBTD1 RNA expression in tumor versus normal tissue (log2 FC = +1.423, t-test p < 0.001).
This table shows molecular features associated with UBTD1 in patient tissues and cancer cell lines. In patient samples, UBTD1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBTD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BONE.
